In collaboration with AstraZeneca, we are launching a PDX consortium to develop a collaborative, pre-competitive PDX resource.
The objective of the project is to provide a resource for streamlined discovery and access to molecular data from PDX models to suit specific needs in oncology research. Use the following resources to find out more:
For any further information, or to retrieve the project proposal and consortium member agreement:Contact Us
Tumour cells from a cancer patient are transplanted into special mice that do not reject human cells.
The transplant in the mouse continues to grow within the tumour microenvironment.
Each PDX comes from a single patient and represents a tumour with a unique molecular profile.
Every PDX model - like every cancer - has a unique genetic make-up.
Researchers across many labs, including the PDX providers, are using a variety of techniques to map the genomic characteristics of each model, including genotyping, gene expression and whole-genome sequencing.
The Repositive PDX resource is a catalogue of the genomic data resources for PDX data, allowing researchers to directly find data for their PDX model of interest.
By maximising availability and reuse of existing PDX data, the oncology research units will shorten their time for data access and speed up their decision process for conducting PDX experiments.